Detalles de la búsqueda
1.
Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy.
Cytotherapy;
24(7): 720-732, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35570170
2.
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305.
Clin Cancer Res;
29(6): 1086-1101, 2023 03 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36355054
3.
Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.
Cancer Res;
77(10): 2686-2698, 2017 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28283653
4.
Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.
Neoplasia;
17(8): 661-70, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26408258
5.
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways.
Mol Cancer Ther;
14(7): 1637-49, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25948294
6.
Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling.
Mol Cancer Ther;
13(2): 386-98, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24344235
7.
Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
Cancer Res;
71(3): 1029-40, 2011 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21245093
8.
Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
Mol Cancer Ther;
8(8): 2131-41, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19671750
Resultados
1 -
8
de 8
1
Próxima >
>>